Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2571 studies found for:    "Lymphoma, Non-Hodgkin"
Show Display Options
Download search resultsDownload the search results for:
"Lymphoma, Non-Hodgkin" (2571 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Active, not recruiting Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Conditions: Lymphoma, Non-Hodgkin;   Hodgkin Disease;   Multiple Myeloma
Interventions: Drug: TXA127;   Drug: Placebo
2 Completed Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: recombinant human interleukin 21 and rituximab
3 Completed A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   HIV Infections
Intervention: Drug: Mitoguazone
4 Recruiting Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Procedure: Stem cell infusion;   Procedure: TLI;   Drug: Anti-thymocyte globulin;   Drug: Solumedrol;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
5 Completed Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients
Conditions: Neoplasms by Site;   Lymphoma, Non-hodgkin;   Hodgkin Disease;   Multiple Myeloma;   Leukemia, Lymphocytic, Chronic
Intervention: Drug: PCI-24781
6 Recruiting Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit
Conditions: Leukemia, Lymphocytic, Acute;   Leukemia, Lymphocytic, Chronic;   Leukemia, Myelocytic, Acute;   Leukemia, Myeloid, Chronic;   Lymphoma, Non-Hodgkin;   Lymphoma, Hodgkins
Intervention: Other: Haploidentical/cord transplant
7 Completed Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies
Conditions: Lymphoma, Non-Hodgkin;   Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic
Intervention: Drug: SGN-35
8 Approved for marketing A Treatment-Option Study of Brentuximab Vedotin in Patients With Progression of Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
Conditions: Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Intervention: Drug: brentuximab vedotin
9 Completed A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma
Conditions: Carcinoma, Renal Cell;   Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-75
10 Completed Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma
Conditions: Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-40
11 Active, not recruiting A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
Conditions: Lymphoma, B-Cell;   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Non-Hodgkin;   Lymphoma, T-Cell
Interventions: Drug: brentuximab vedotin;   Drug: rituximab
12 Completed Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL
Conditions: Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Non-Hodgkin
Interventions: Drug: SGN-40;   Drug: rituximab;   Drug: gemcitabine
13 Completed Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)
Conditions: Carcinomas;   Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin;   Neoplasms
Interventions: Drug: brentuximab vedotin;   Drug: rifampin;   Drug: midazolam;   Drug: ketoconazole
14 Terminated A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies
Conditions: Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Interventions: Drug: SGN-35;   Drug: gemcitabine
15 Completed
Has Results
Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma
Conditions: Lymphoma;   Hodgkin Disease;   Lymphoma, Non-Hodgkin
Intervention: Drug: PCI-24781
16 Active, not recruiting
Has Results
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
Conditions: Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Intervention: Drug: brentuximab vedotin
17 Recruiting ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
Conditions: Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin;   Lymphoma, T-Cell
Interventions: Drug: brentuximab vedotin;   Drug: doxorubicin;   Drug: prednisone;   Drug: vincristine;   Drug: cyclophosphamide
18 Terminated
Has Results
T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE
Conditions: Leukemia;   Cancer;   Lymphoma;   Lymphoma, Hodgkin;   Lymphoma, Non-Hodgkin
Interventions: Drug: Ara C;   Drug: Mesna;   Drug: Cyclophosphamide;   Radiation: TBI-Total Body Irradiation
19 Completed A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
Conditions: Lymphoma, Non-Hodgkin;   Multiple Myeloma;   Giant Lymph Node Hyperplasia
Intervention: Drug: CNTO 328
20 Completed Gene Therapy in HIV-Positive Patients With Non-Hodgkin's Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   HIV Infections
Intervention: Drug: Peripheral blood stem cells

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years